Cellular Biomedicine Group Inc (CBMG)


Stock Price Forecast

Feb. 19, 2021


Forecasted Returns

7 Days Predict

30 Days Predict

90 Days Predict


Forecasted Market-Excess Returns

7 Days Predict

30 Days Predict

90 Days Predict

Loading Cellular Biomedicine Group Inc chart...

About the Company

Regeneration in biology is the process of renewal, restoration, and tissue growth that makes genomes, cells, organisms, and ecosystems resilient to natural fluctuations or events that cause disturbance or damage. Every species is capable of regeneration, from bacteria to humans. Regeneration can either be complete where the new tissue is the same as the lost tissue, or incomplete after which the necrotic tissue becomes fibrotic. At its most elementary level, regeneration is mediated by the molecular processes of gene regulation and involves the cellular processes of cell proliferation, morphogenesis and cell differentiation. Regeneration in biology, however, mainly refers to the morphogenic processes that characterize the phenotypic plasticity of traits allowing multi-cellular organisms to repair and maintain the integrity of their physiological and morphological states. Above the genetic level, regeneration is fundamentally regulated by asexual cellular processes. Regeneration is different from reproduction. For example, hydra perform regeneration but reproduce by the method of budding. The regenerative process occurs in two multi-step phases: the preparation phase and the redevelopment phase. Regeneration begins with an amputation which triggers the first phase. Right after the amputation, migrating epidermal cells form a wound epithelium which thickens, through cell division, throughout the first phase to form a cap around the site of the wound. The cells underneath this cap then begin to rapidly divide and form a cone shaped end to the amputation known as a blastema. Included in the blastema are skin, muscle, and cartilage cells that de-differentiate and become similar to stem cells in that they can become multiple types of cells. Cells differentiate to the same purpose they originally filled meaning skin cells again become skin cells and muscle cells become muscles. These de-differentiated cells divide until enough cells are available at which point they differentiate again and the shape of the blastema begins to flatten out. It is at this point that the second phase begins, the redevelopment of the limb. In this stage, genes signal to the cells to differentiate themselves and the various parts of the limb are developed. The end result is a limb that looks and operates identically to the one that was lost, usually without any visual indication that the limb is newly generated. The hydra and the planarian flatworm have long served as model organisms for their highly adaptive regenerative capabilities. Once wounded, their cells become activated and restore the organs back to their pre-existing state. The Caudata ("urodeles"; salamanders and newts), an order of tailed amphibians, is possibly the most adept vertebrate group at regeneration, given their capability of regenerating limbs, tails, jaws, eyes and a variety of internal structures. The regeneration of organs is a common and widespread adaptive capability among metazoan creatures. In a related context, some animals are able to reproduce asexually through fragmentation, budding, or fission. A planarian parent, for example, will constrict, split in the middle, and each half generates a new end to form two clones of the original. Echinoderms (such as the sea star), crayfish, many reptiles, and amphibians exhibit remarkable examples of tissue regeneration. The case of autotomy, for example, serves as a defensive function as the animal detaches a limb or tail to avoid capture. After the limb or tail has been autotomized, cells move into action and the tissues will regenerate. In some cases a shed limb can itself regenerate a new individual. Limited regeneration of limbs occurs in most fishes and salamanders, and tail regeneration takes place in larval frogs and toads (but not adults). The whole limb of a salamander or a triton will grow repeatedly after amputation. In reptiles, chelonians, crocodilians and snakes are unable to regenerate lost parts, but many (not all) kinds of lizards, geckos and iguanas possess regeneration capacity in a high degree. Usually, it involves dropping a section of their tail and regenerating it as part of a defense mechanism. While escaping a predator, if the predator catches the tail, it will disconnect.

CEO

Tony Liu

Exchange

NASDAQ/NGS (GLOBAL SELECT MARKET)

Website

http://www.cellbiomedgroup.com/

$0M

Total Revenue

217

Employees

$375M

Market Capitalization

-7.00

Price/Earning ratio

Fundamental Data and Insider Transactions (Quarterly data) Full Screen

Loading the fundamentals chart...

Latest $CBMG News

NOVARTIS AG's Net Worth

6d ago, source: Benzinga.com

NOVARTIS AG has an estimated net worth of $1.34 Billion. This is based on reported shares across multiple companies, which include Cellular Biomedicine Group, Inc., Poseida Therapeutics, Inc ...

J&J builds in CAR-T with $245m Cellular Biomedicine deal

1y ago, source: pharmaphorum

With the Cellular Biomedicine candidates, the big pharma will start to muscle in on territory in NHL already being pioneered by early CAR-T developers Gilead Sciences and Novartis with Yescarta ...

Johnson & Johnson Ignites CAR-T Ambitions With Licensing Pact With Cellular Biomedicine

1y ago, source: Yahoo Finanzas

Johnson & Johnson's (NYSE: JNJ) pharma unit Janssen entered into a worldwide collaboration and license agreement with Cellular Biomedicine Group Inc to develop, manufacture and commercialize ...

HHLR ADVISORS, LTD.'s Net Worth

14d ago, source: Benzinga.com

This is based on reported shares across multiple companies, which include ArriVent Biopharma, Inc., BeiGene, Ltd., and Cellular Biomedicine Group, Inc.. Attention insiders: Dive deeper into market ...

Intra-Cellular: Q1 Earnings Snapshot

1d ago, source:

(ITCI) on Tuesday reported a loss of $15.2 million in its first quarter. On a per-share basis, the New York-based company said it had ...

TIGO Stock Earnings: Millicom Intl Cellular Beats EPS, Beats Revenue for Q1 2024

on MSN ago, source:

TIGO stock results show that Millicom Intl Cellular beat analyst estimates for earnings per share and beat on revenue for the ...

Intra-Cellular Therapies Reports First Quarter 2024 Financial Results

1d ago, source:

CAPLYTA Q1 2024 net product sales were $144.8 million, compared to $94.7 million for the same period in 2023, representing a 53% increase CAPLYTA’s strong prescription uptake continues: Q1 2024 ...

United States Cellular Q1 2024 Earnings Preview

6d ago, source: Seeking Alpha on MSN

United States Cellular (NYSE:USM) is scheduled to announce Q1 earnings results on Friday, May 3rd, before market open. The consensus EPS Estimate is $1.09 (+626.7% Y/Y) and the consensus Revenue ...

Millicom International Cellular S.A. reports Q1 results

on MSN ago, source:

Q1 Revenue of $1.49B (+8.8% Y/Y). Net income of $92 million in Q1 2024 was up strongly from $3 million in Q1 2023, reflecting the significant increase in operating profit. More on Millicom ...

Intra-Cellular Therapies, Inc. (ITCI)

8d ago, source: Yahoo Finance

NEW YORK, April 30, 2024 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central ...

Millicom International Cellular S.A. Q1 2024 Earnings Preview

on MSN ago, source:

Millicom International Cellular S.A. (NASDAQ:TIGO) is scheduled to announce Q1 earnings results on Wednesday, May 8th, before market open. The consensus EPS Estimate is $0.57 (+2750.0% Y/Y) and the ...

Biomedicine and Law

3y ago, source: Drexel University

The Masters of Science in Biomedicine and Law graduate degree program (BMLA) provides comprehensive training in technical and practical aspects of science and innovation, as well as in the legal ...

Latest Neutral (free) Forecasts

STRONG BUY BUY NEUTRAL SELL STRONG SELL ALL

Loading the latest forecasts...

My Portfolio

Loading your portfolio...